Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Authors: Luis A. Díaz, Kai‐Keen Shiu, Tae‐Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J.A. Punt, Denis Smith, Rocio García‐Carbonero, Manuel Benavides, Peter Gibbs, Christelle de la Fourchardière, Fernando Rivera, Elena Élez, Dung T. Le, Takayuki Yoshino, Wen Yan Zhong, David R. Fogelman, Patricia Marinello, Thierry André - The Lancet 2022 cited by 894